, /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: ), a global leader in pet healthcare innovation, announces the launch of the Catalyst Pancreatic Lipase Test, a single-slide solution for canine and feline patients suspected of pancreatitis. With the innovative load-and-go workflow of the Catalyst analyzers, the test can run effortlessly alongside chemistry profiles, leading to a faster path to diagnosis and enhanced patient outcomes.
The Catalyst Pancreatic Lipase Test will be available in the U.S. and this September, with a global rollout to the over 70,000 Catalyst installed base planned to begin in the fourth quarter of 2024.
Pancreatitis is a common disease among cats and dogs, and while treatable, it can prove fatal if not caught early. Diagnosing pancreatitis can be difficult due to its nonspecific symptoms and subtle clinical signs, including vomiting and weight loss, which are among the 10 most frequently recorded clinical signs in primary care clinics. Now, with the Catalyst Pancreatic Lipase Test, veterinarians can receive quantitative results in under 10 minutes.
By delivering quantitative diagnostic insights during the patient visit, the new test empowers veterinarians to confidently confirm or rule out pancreatitis and immediately begin treatment, saving crucial time and improving patient outcomes. "The Catalyst Pancreatic Lipase Test marks the tenth menu addition launched for the Catalyst platform since 2012, reinforcing our commitment to extend the clinical .
